

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 020618-000920US
Client Reference No.: N8-80PAT3

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AUGUST 8, 2003

TOWNSEND and TOWNSEND and CREW LLP

By:

Nicole M. Burke

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gregory S. Hageman

Application No.: 10/084,639

Filed: February 25, 2002

For: DIAGNOSTICS AND
THERAPEUTICS FOR MACULAR
DEGENERATION-RELATED
DISORDERS

Examiner: Not yet assigned

Art Unit: 1644

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
SLA:mcl
DE 7089919 v1



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of

Complete if Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	020618-000920US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	A1	US-5,472,939	12-05-1995	Fearon, et al	
	A2	US-5,681,571	10-28-1997	Holmgren et al.	
	A3	US-5,773,573	06-30-1998	Holms	
	A4	US-5,843,449	12-01-1998	Boots et al.	
	A5	US-5,951,984	09-14-1999	Kaneko et al.	
	A6	US-6,087,120	07-11-2000	Van Oeveren et al.	
	A7	US-6,103,235	08-15-2000	Neville et al.	
	A8	US-6,153,203	11-28-2000	Holmgren et al.	
	A9	US-2002/0015957 A1	02-07-2002	Hageman et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	PCT	WO 90/15152	A1	12-13-1990			
	B2	PCT	WO 95/17673	A	06-29-1995			
	B3	PCT	WO 00/52479	A2	09-08-2000			<input type="checkbox"/>

Examiner
Signature

Date
Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DE 7089919 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **9****Complete if Known**

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	020618-000920US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ABRAHA, A. and LUZIO, J.; "Inhibition of the formation of the complement membrane-attack complex by a monoclonal antibody to the complement component C8 α Subunit", <i>Biochem J.</i> 1989, pp. 933-6; 264, Great Britain.	
	C2	AKIYAMA, H. et al; "Inflammation and Alzheimer's disease"; <i>Neurobiol of Aging</i> 21; May-June 2000; pp. 383-421; Volume 21, No. 3	
	C3	ALLIKMETS, R. et al; "Mutation of the Stargardt Disease Gene (ABCR) in Age-Related Macular Degeneration", <i>Science</i> , September 19, 1997; pp. 1805-1807, Vol. 277	
	C4	AUDA, G. et al; "Measurement of complement activation products in patients with chronic rheumatic diseases", <i>Rheumatology International</i> ; 1990, 10(5):pp. 185-189, Springer-Verlag	
	C5	BAATRUP, G. et al; "Effects of coagulation temperature on measurements of complement function in serum samples from patients with systemic lupus erythematosus", <i>Annals of Rheumatic Disease</i> ; 1992, 51(7):892-897	
	C6	BACHINSKY, D. et al; "Detection of Two Forms of GP330", <i>American Journal of Pathology</i> .; August 1993, pp. 598-611, Vol. 143, No. 2	
	C7	BHAKDI, S. & TRANUM-JENSEN, J.; "Membrane Damage by Complement", <i>Biochimica et Biophysica Acta</i> ; 1983, pp. 343-372; 737, Elsevier Science Publishers B.V.	
	C8	BORA, N.S. et al.; "Differential expression of the complement regulatory proteins in the human eye", <i>Investigative Ophthalmology & Visual Science</i> ; December 1993, pp. 3579-3584, Vol. 34, No. 13	
	C9	BRALEY-MULLEN; "Activation of Distinct Subsets of T Suppressor Cells with Type III Pneumococcal Polysaccharide Coupled to Syngeneic Spleen Cells", <i>Immunological Tolerance To Self and Non-Self</i> , Annals of New York Academy of Science, 1982, pp. 156-166, Vol. 392.	
	C10	BURGER, R. et al; "The C Terminus of the Anaphylatoxin C3a Generated Upon Complement Activation Represents a Neoantigenic Determinant with Diagnostic Potential", <i>Journal of Immunology</i> , July 15, 1988; pp. 553-558, Vol. 141, No. 2, Printed in the U.S.A.	
	C11	BUYON, J. et al.; "Assessment of Disease Activity and Impending Flare in Patients with Systemic Lupus Erythematosus", <i>Arthritis and Rheumatism</i> ; September 1992, pp. 1028-1037, Vol. 35, No. 9	
	C12	CAMPBELL, R. et al; "An Anion Binding Study of Vanadyl(IV) Human Serotransferrin", <i>Journal of Biological Chemistry</i> ; 1977, pp. 5996-6001, Vol. 252, No. 17, Printed in the U.S.A.	
	C13	CARAHAR, E.M. et al; "Evidence for enhanced rates of complement activation in serum from patients with newly diagnosed insulin-dependent diabetes mellitus exposed to rat islet cells and complement-dependent induction of islet cell apoptosis.", <i>Journal of Endocrinology</i> ; 1999, pp. 143-153, Vol. 162, No. 1, Printed in Great Britain	
	C14	CHENOWETH, D. et al; "Complement Activation During Cardiopulmonary Bypass", <i>New England Journal of Medicine</i> ; February 26, 1981; pp. 497-502, Vol. 304, No. 9, Printed in the U.S.A.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of 9

Complete if Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	020618-000920US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C15	CHAIN, B. et al; "Improvement of the in vitro T cell proliferation assay by a modified method that separates the antigen recognition and IL-2-dependent steps.", <i>Journal of Immunological Methods</i> ; 1987, pp. 221-228, Vol. 99.	
	C16	DEBROCK, S. and DECLERCK, P.; "Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serin proteinases.", <i>FEBS Letters</i> ; 1995, pp.243-246, Vol. 376.	
	C17	DELORI, F. and BEN-SIRA, I.; "Excitation and emission spectra of fluorescein dye in the human ocular fundus.", <i>Investigative Ophthalmology</i> ; June 1975, pp.487-492, Vol 14, No. 6.	
	C18	DELORI, F. et al; "In Vivo Fluorescence of the Ocular Fundus Exhibits Retinal Pigment Epithelium Lipofuscin Characteristics", <i>Investigative Ophthalmology & Visual Science</i> ; March 1995, pp. 718-729, Vol. 36, No. 3.	
	C19	DETRICK, B. et al.; "Class II Antigen Expression and Gamma Interferon Modulation of Monocytes and Retinal Pigment Epithelial Cells from Patients with Retinitis Pigmentosa", <i>Clinical Immunology and Immunopathology</i> , August 1985, pp. 201-211, Vol. 36, No. 2, San Diego, CA, U.S.A.	
	C20	EDWARDS, A. et al; "Malattia Leventinese: Refinement of the Genetic Locus and Phenotypic Variability in Autosomal Dominant Macular Drusen", <i>American Journal of Ophthalmology</i> ; September 1998, pp. 417-424, Vol. 126, Elsevier Science Inc.	
	C21	EGERTON, M. et al; "Identification of Ezrin as an 81-kDa Tyrosin-Phosphorylated Protein in T Cells", <i>The Journal of Immunology</i> , September 15, 1992; pp. 1847-1852, Vol. 149, No. 6, Printed in the U.S.A.	
	C22	ENK, C. et al; "A Standardized Human T-lymphocyte Proliferation Assay for Detecting Soluble Accessory Factors From Monocytes", <i>Acta Pathol Microbiol Immunol Scand [C]</i> , 1984, pp. 93-100, Vol. 92, No. 2.	
	C23	EPSTEIN, G.A. and RABB, M.F.; "Adult vitelliform macular degeneration: diagnosis and natural history"; <i>British Journal of Ophthalmology</i> , 1980, pp. 733-40, Vol. 64.	
	C24	FELBOR, U. et al; "Adult vitelliform Macular Dystrophy Is Frequently Associated With Mutations in the Peripherin/RDS Gene", <i>Human Mutation</i> ; 1997, pp. 301-309, Vol. 10.	
	C25	FELBOR, U. et al; "Autosomal Recessive Sorsby Fundus Dystrophy Revisited: Molecular Evidence for Dominant Inheritance", <i>American Journal of Human Genetics</i> ; 1997, pp.57-62, Vol. 60.	
	C26	FITZGIBBON, J. et al; "Localisation of the human blue cone pigment gene to chromosome band 7q31.3-32", <i>Human Genetics</i> ; 1994, pp. 79-80, Vol. 93.	
	C27	FORSTROM, J.W. et al; Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody", <i>Nature</i> ; June 16, 1983; pp. 627-629, Vol. 303.	
	C28	GILTAY, R. et al; "Sequence, Recombinant Expression and Tissue Localization of Two Novel Extracellular Matrix Proteins, fibulin-3 and fibulin-4", <i>Matrix Biol</i> , October 1999, pp. 469-480, Vol. 18, No. 5.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/084,639		
		Filing Date	February 25, 2002		
		First Named Inventor	Hageman, Gregory S., et. al.		
		Art Unit	1644		
		Examiner Name	Not yet assigned		
Sheet	4	of	9	Attorney Docket Number	020618-000920US


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C29	GORSKI, J.; "Quantitation of Human Complement Fragment C4ai in Physiological Fluids by Competitive Inhibition Radioimmune Assay", <i>Journal of Immunological Methods</i> ; 1981, pp. 61-73, Vol. 47, Elsevier/North-Holland Biomedical Press.	
	C30	GOSLINGS W., et al.; "Membrane-Bound Regulators of Complement Activation in Uveal Melanomas. CD46, CD55, and CD59 in Uveal Melanomas"; <i>Investigative Ophthalmology & Visual Science</i> , August 1996, pp. 1884-1891, Vol. 37, No. 9.	
	C31	GREEN, W.R.; "Histopathology of age-related macular degeneration", <i>Molecular Vision</i> , November 1999, Vol. 5, No. 27.	
	C32	GRIESINGER, I.B. et al; Macular Degeneration with Highly Variable Phenotype Localized to Chromosome 6q." <i>American Journal of Human Genetics</i> ; 63:A30; 1998	
	C33	GURNE, D. et al; "Antiretinal Antibodies in Serum of Patients with Age-related Macular Degeneration", <i>Ophthalmology</i> , May 1991; pp. 602-607, Vol. 98, No. 5.	
	C34	HALLIDAY, W.J. and MALUISH, A.E.; Chapter 1: "Hemocytometer LAI: Immunological Basis and Applications", <i>Assessment of Immune Status by the Leukocyte Adherence Inhibition Test</i> ; 1982; pp. 1-26, Academic Press, Inc; New York	
	C35	HAYAMIZU et al; "Monocyte-derived dendritic cell precursors facilitate tolerance to heart allografts after total lymphoid irradiation", <i>Transplantation</i> , 1998, pp. 1285-1291, Vol. 66, No. 10	
	C36	HINTNER, H. et al; "Vitronectin Shows Complement-Independent Binding to Isolated Keratin Filament Aggregates", <i>Journal of Investigative Dermatology</i> ; November 1989, pp. 656-661, Vol. 93, No. 5.	
	C37	HOLZ, F. et al.; "Patterns of increased in vivo fundus autofluorescence in the junctional zone of geographic atrophy of the retinal pigment epithelium associated with age-related macular degeneration.", <i>Graefes Arch Clin Exp Ophthalmol</i> ; 1999, pp. 145-52, Vol. 237.	
	C38	HUGLI, T.E. and CHENOWETH, D.E.; "Biologically Active Peptides of Complement: Techniques and Significance of C3a and C5a Measurements", <i>Immunoassays: Clinical Laboratory Techniques for the 1980s</i> ; 1980, pp. 443-460.	
	C39	INGLEHEARN, et al; Letter to the Editor entitled, "Loci for Autosomal Dominant Retinitis Pigmentosa and Dominant Cystoid Macular Dystrophy on Chromosome 7p Are Not Allelic", <i>American Journal of Human Genetics</i> ; 1994, pp. 581-582, Vol. 55.	
	C40	JOHNSON, L.V. et al.; "A Potential Role for Immune Complex Pathogenesis in Drusen Formation"; <i>Exp Eye Res</i> , 2000; pp. 441-449, Vol. 70.	
	C41	KAKEHASHI, et al; "Differential Diagnosis of Macular Breaks By Microperimetry Using the Scanning Laser Ophthalmoscope", <i>Jpn J Ophthalmol</i> ; 1996, pp. 116-122; Vol. 40, No. 1.	
	C42	KALUZNY; et al; "The use of indocyanine green angiography in diagnosis of occult choroidal neovascularization in age-related macular degeneration" (title translated), <i>Klinika Oczna</i> ; 1999, pp. 355-359, Vol. 101, No. 5, with abstract.	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute Form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 9

Complete if Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	020618-000920US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C43	KAZEEM, A.A. et al; "Assay of Circulating Immune Complexes by Immunonephelometry Markers of Immunonephropathy Among Young Nigerians", <i>East African Medical Journal</i> ; June 1990, pp. 396-403, Vol. 67, No. 6.	
	C44	KELSELL, R. et al; Letter to the Editor entitled, "Localization of a Gene (CORD7) for a Dominant Cone-Rod Dystrophy to Chromosome 6q", <i>American Journal of Human Genetics</i> , 1998, pp. 274-279, Vol. 63.	
	C45	KIANG, J. et al, "17 β -Estradiol-induced Increases in Glucose-regulated Protein 78kD and 94kD Protect Human Breast Cancer T47-D Cells from Thermal Injury", <i>Chinese Journal of Physiology</i> ; 1997, pp. 213-219, Vol. 40, No. 4.	
	C46	KILPATRICK, J. and VOLANAKIS, J.; "Opsonic Properties of C-Reactive Protein. Stimulation by Phorbolmyristate Acetate Enables Human Neutrophils to Phagocytize C-Reactive Protein-Coated Cells", <i>The Journal of Immunology</i> , May 1985, pp. 3364-3370, Vol. 134, No. 5.	
	C47	KITA, T. et al; "Atherosclerosis V: The Fifth Saratoga International Conference. Oxidized-LDL and Atherosclerosis Role of LOX-1", <i>Annals of the New York Academy of Sciences</i> ; 2000, pp. 95-100, Vol. 902.	
	C48	KLEIN, M. et al; "Age-Related Macular Degeneration. Clinical Features in a Large Family and Linkage to Chromosome 1q.", <i>Arch. Ophthalmol</i> ; August 1998, pp. 1082-1088, Vol. 116.	
	C49	KOHNO, T. et al.; "Detection of Choroidal Neovascularization in Age-related Macular Degeneration Using Subtraction Methods in Indocyanine Green Angiography", <i>Bull Soc Belge Ophthalmol</i> ; 1995, pp. 81-88, Vol. 259.	
	C50	KOPPI, T. and HALLIDAY, W.J.; "Further Characterization of the Cells Involved in Leukocyte Adherence Inhibition with Murine Tumor Extracts", <i>Cellular Immunology</i> ; 1982; pp. 394-406, Vol. 66.	
	C51	KOVACS, H. et al; "Evidence That C1q Binds Specifically to C ₂ -like Immunoglobulin γ Motifs Present in the Autoantigen Calreticulin and Interferes with Complement Activation", <i>Biochemistry</i> ; 1998, pp. 17865-17874, Vol. 37, No. 51.	
	C52	KRAPF, F. et al; "Determination of Complement Activating Circulating Immune Complexes and an Example for Antigen Specific Immune Complex Assays", <i>Journal of Clinical Lab Immunology</i> ; 1986, pp. 183-187, Vol. 21.	
	C53	KUCK, H. et al.; Diagnosis of Occult Subretinal Neovascularization in Age-related Macular Degeneration by Infrared Scanning Laser Videoangiography", <i>Retina</i> ; 1993, pp. 36-29, Vol. 13, No. 1.	
	C54	KYLSTRA, J.A. et al; Letter to the Journal entitled, "Cone-rod retinal dystrophy in a patient with neurofibromatosis type 1", <i>Canadian Journal of Ophthalmology</i> ; 1993, pp. 79-80, Vol. 28, No. 2.	
	C55	LANGLOIS, P. et al; "Plasma concentrations of complement-activation complexes correlate with disease activity in patients diagnosed with isolated central nervous system vasculitis", <i>Journal of Allergy Clinical Immunology</i> ; January 1989, pp. 11-16, Vol. 83, No. 1.	
	C56	LAWN et al; "The Sequence of Human Serum Albumin cDNA and Its Expression in E. coli", <i>Nucleic Acids Research</i> , 1981, pp. 6103-6114, Vol. 9, No. 22	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	020618-000920US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C57	LI, X. et al.; "A pineal relutatory element (PIRE) mediates transactivation by the pineal/retina-specific transcription factor CRX", <i>Proc. Natl. Acad. Sci. USA</i> ; 1998, pp. 1876-1881, Vol. 95.	
	C58	LINDER, E. et al; "An Immunofluorescence Assay for Complement Activation by the Classical Pathway", <i>Journal of Immunological Methods</i> ; 1981, pp. 49-59, Vol. 47.	
	C59	LOTERY, A.J. et al; "Localisation of a Gene for Central Areolar Choroidal Dystrophy to Chromosome 17p", <i>Investigative Ophthalmology & Visual Science</i> ; February 15, 1996; pp. 1124, Vol. 37, No. 3. (Abstract only)	
	C60	LUBINSKI, W. et al; "Foveal electroretinogram-application in diagnosis of macular diseases. Preliminary report.", <i>Klin Oczna</i> ; 1998, pp. 263-268, Vol. 100, No. 5. (Translated abstract of document included)	
	C61	LYNCH, N. et al; "Characterisation of the rat and mouse homologues of gC1qBP, a 33 kDa glycoprotein that binds to the globular 'heads' of C1q", <i>FEBS Letters</i> ; 1997, pp. 111-114, Vol. 418.	
	C62	MAHANT, S., et al.; "Retinal dystrophy in 18q- (de Grouchy) syndrome.", <i>Am. J. Hum. Genet.</i> ; 1995, p. A96, Vol. 57. (Abstract only)	
	C63	MARMORSTEIN, ALAN D., et al; "Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium", <i>PNAS</i> ; November 7, 2000; pp. 12758-12763; Vol. 97, No. 23	
	C64	MARQUARDT, A. et al; "Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease)", <i>Human Molecular Genetics</i> ; 1998, pp. 1517-1525, Vol. 7, No. 9, Oxford University Press.	
	C65	MARX; "Testing of Autoimmune Therapy Begins", <i>Science</i> , April 1991, pp. 27-28, Vol. 252	
	C66	METZLER and WRAITH; "Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity", <i>International Immunology</i> , 1993, pp. 1159-1165, Vol. 5, No. 9	
	C67	MILIS, L. et al; "Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9", <i>Clin Exp Immunol.</i> ; 1993, pp. 114-119, Vol. 92.	
	C68	MINH, DO-QUANG et al; "Serial complement measurements in patients with leukaemia", <i>Clin Lab Haematol.</i> ; 1983, pp. 23-34, Vol. 5.	
	C69	MOLD, C. et al; "CR2 is a Complement Activator and the Covalent Binding Site for C3 During Alternative Pathway Activation by Raji Cells", <i>Journal of Immunology</i> ; March 15, 1988; pp. 1923-1929, Vol. 140, No. 6.	
	C70	MOUSA, S. et al. "Role of Hypoxia and Extracellular Matrix-Integrin Binding in the Modulation of Angiogenic Growth Factors Secretion by Retinal Pigmented Epithelial Cells", <i>Journal of Cellular Biochemistry</i> , 1999, pp. 135-143, Vol. 74	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 9

Complete if Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	020618-000920US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C71	MULLINS, R. et al.; "Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease", <i>The FASEB Journal</i> ; May 2000, pp. 835-846, Vol. 14.	
	C72	MUNROE, P. et al; "Spectrum of Mutations in the Batten Disease Gene, CLN3", <i>American Journal of Human Genetics</i> ; 1997, pp. 310-316, Vol. 61.	
	C73	NEWELL, S., et al.; "Hemolytic and antigenic measurements of complement. A comparison of serum and plasma samples in normal individuals and patients"; <i>J Lab Clin Med</i> ; September 1982; pp. 437-444; Volume 100, No. 3.	
	C74	NG, Y.C. et al.; "Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions", <i>Clin Exp Immunol.</i> ; 1988, pp. 481-485, Vol. 71.	
	C75	PADMA, T. and MURTY, J.S., "Association of Genetic Markers with Some Eye Diseases", <i>Acta Anthropogenetica</i> , 1983, pp. 1-12, Vol. 7, No. 1.	
	C76	PAYNE, A. et al; "A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1", <i>Human Molecular Genetics</i> ; 1998, pp. 273-277, Vol. 7, No. 2, Oxford University Press.	
	C77	PENFOLD, P. et al; "Autoantibodies to retinal astrocytes associated with age-related macular degeneration", <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 1990, pp. 270-274, Vol. 228.	
	C78	PINTÉR, C. et al; "Presence of autoantibodies against complement regulatory proteins in relapsing-remitting multiple sclerosis", <i>Journal of Neurovirology</i> ; 2000, pp. S42-S46, Vol. 6, Suppl. 2, Macmillan Publishers Ltd.	
	C79	QUAX-JEUKEN, Y. et al; "βs-Crystallin: structure and evolution of a distinct member of the βγ-superfamily", <i>EMBO Journal</i> ; 1985, pp. 2597-2602, Vol. 4, No. 10.	
	C80	RABB, M. et al, "A North Carolina Macular Dystrophy Phenotype in a Belizean Family Maps to the MCDR1 Locus", <i>American Journal of Ophthalmology</i> , April 1998, pp. 502-508, Vol. 125, No. 4.	
	C81	RATNOFF, W. et al.; "Immunohistochemical Localization of C9 Neoantigen and the Terminal Complement Inhibitory Protein CD59 in Human Endometrium", <i>American Journal of Reproductive Immunology</i> ; 1995, pp. 72-79, Vol. 34, Munksgaard, Copenhagen.	
	C82	RAVELLI, A. et al; "IgG autoantibodies to complement C1q in pediatric-onset systemic lupus erythematosus", <i>Clinical and Experimental Rheumatology</i> ; 1997, pp. 215-219, Vol. 15.	
	C83	REAVEN, PETER; "Mechanisms of Atherosclerosis: Role of LDL Oxidation", <i>Free Radicals in Diagnostic Medicine</i> , 1994, pp. 113-128, Plenum Press, New York, U.S.A.	
	C84	RODRICK, M. et al; "An Evaluation of Two Antigen Nonspecific Assays for Circulating Immune Complexes Using an Model System", <i>J. Clin Lab Immunol</i> ; 1982, pp. 193-198, Vol. 7, No. 3.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **8** of **9****Complete if Known**

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	020618-000920US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C85	SACKS, J.G. et al; "The Pathogenesis of Optic Nerve Drusen", <i>Archives of Ophthalmology</i> , March 1997, pp. 425-428, Vol. 95, No. 3.	
	C86	SEYMOUR, A. et al; "Linkage Analysis of X-linked Cone-Rod Dystrophy: Localization to Xp11.4 and Definition of a Locus Distinct from RP2 and RP3", <i>Am. J. Hum. Genet.</i> ; 1998, pp. 122-129, Vol. 62.	
	C87	SLINGSBY, C. and BATEMAN, O.A.; "Rapid Separation of Bovine β -Crystallin Subunits β B1, β B2, β B3, β A3 and β A4", <i>Exp Eye Res</i> ; 1990, pp. 21-26, Vol. 51.	
	C88	SMALL, K. et al.; "Mapping of Autosomal Dominant Cone Degeneration to Chromosome 17p", <i>American Journal of Ophthalmology</i> ; 1996, pp. 13-18, Vol. 121, No. 1.	
	C89	SPRAUL, et al; "Optical Coherence Tomography of Age-Related Macular Degeneration. Correlation of Diagnostic Techniques of Fluorescence angiography and OCT" (title translated) <i>Klin Monatsbl Augenheilkd</i> ; March 1998, pp. 141-148, Vol. 212.	
	C90	STONE, EDWIN M., et al.; "A single <i>EFEMP1</i> mutation associated with both Malattia Leventinese and Doyme honeycomb retinal dystrophy", <i>Nature Genetics</i> ; June 1999; pp. 199-202; Volume 22.	
	C91	STRIFE, C. et al; "Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis", <i>The Journal of Pediatrics</i> ; May 1990, pp. S98-S102, Vol. 116, No. 5.	
	C92	SUZUKI et al.; "Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin", <i>EMBO J</i> , 1985, pp. 2519-2524, Vol. 4, No. 10	
	C93	TANAKA, S. et al; "Assay of classical and alternate pathway activities of murine complement using antibody-sensitized rabbit erythrocytes", <i>Journal of Immunological Methods</i> ; 1986, pp. 161-170, Vol. 86, Elsevier Science Publishers B.V.	
	C94	THOMSON et al; "Microchimerism, Dendritic Cell Progenitors and Transplantation Tolerance", <i>Stem Cells</i> ; 1995, pp. 622-639, Vol. 13	
	C95	TOMIMORI-YAMASHITA, J. et al; "Antibody-based enzyme-linked immunosorbent assay for determination of anti-PGL-I specific circulating immune complex in leprosy patients.", <i>Lepr Rev</i> ; 1999, pp. 261-271, Vol. 70.	
	C96	TRAN, H. et al.; "Human Fibulin-1D: Molecular Cloning, Expression and Similarity with S1-5 Protein, a New Member of the Fibulin Gene Family", <i>Matrix Biology</i> , 1997, pp. 479-493, Vol. 15	
	C97	TRENTHAM et al; "Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis", <i>Science</i> ; 1993, pp. 1727-1730, Vol. 261	
	C98	TSCHOPP, J. et al.; "Clusterin, the Human Apolipoprotein and Complement Inhibitor, Binds to Complement C7, C8 β , and the b Domain of C9", <i>Journal of Immunology</i> ; August 15, 1993; pp. 2159-2165, Vol. 151, No. 4, Printed in the U.S.A.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 9

Complete if Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	020618-000920US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C99	VAN DIJK, H. et al.; "Determination of Alternative Pathway of Complement Activity in Mouse Serum Using Rabbit Erythrocytes", <i>Journal of Immunological Methods</i> ; 1890, pp.29-39, Vol. 36, Elsevier/North-Holland Biomedical Press.	
	C100	VOLANAKIS, J.; C-Reactive Protein and the Plasma Protein Response to Tissue Injury. Part IV. Biological Properties and Function of CRP and SAP: "Complement Activation by C-Reactive Protein Complexes", <i>Annals of the New York Academy of Sciences</i> ; 1982, pp. 235-50, Vol. 389.	
	C101	WARBURG, M., et al; "Deletion Mapping of a Retinal Cone-Rod Dystrophy: Assignment to 18q211", <i>American Journal of Medical Genetics</i> ; 1991, pp. 288-293, Vol. 39.	
	C102	WEXLER et al; "Primary amino acid sequence and structure of human pyruvate carboxylase", <i>Biochimica et Biophysica Acta</i> , 1994, pp. 46-52, Vol. 1227	
	C103	YAMANAKA, R. et al; "CCAAT/enhancer binding protein ϵ is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing.", <i>Proc Natl Acad Sci USA</i> ; June 1997, pp. 6462-6467, Vol. 94.	
	C104	YUZAWA, M. et al; "Clinical evaluation of indocyanine green video-angiography in the diagnosis of choroidal neovascular membrane associated with age-related macular degeneration", <i>European Journal of Ophthalmology</i> ; 1992, pp. 115-121, Vol. 2, No. 3.	
	C105	ZHANG, K. et al; "A dominant Stargardt's Macular Dystrophy Locus Maps to Chromosome 13q34", <i>Arch. Ophthalmol.</i> ; June 1994, pp. 759-764, Vol. 112.	
	C106	ZHANG, Y. et al; "Lysis via the lectin pathway of complement activation: minireview and lectin pathway enhancement of endotoxin-initiated hemolysis"; <i>Immunopharmacology</i> ; May 1999; pp. 81-90; Volume 42	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.